Michael Mannstadt, MD (he/him/his)

Chief, Endocrine Unit
Massachusetts General Hospital and Harvard Medical School
Boston, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• ORF16-04 - Encaleret Restores Mineral Homeostasis in Autosomal Dominant Hypocalcemia Type 1 (ADH1): Primary Results from the Phase 3 CALIBRATE Trial

  Saturday, June 13, 2026
  2:00 PM - 2:15 PM CT

• MON-748 - Title: Data-Driven Genetic Clustering of Bone Mineral Density Loci Reveals Heterogeneous Mechanistic Pathways Associated with Osteoporosis

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-761 - Genetic Testing of over 400 Individuals with Non-Surgical Hypoparathyroidism Shows Gain-of-Function CASR Variants as the Most Common Genetic Cause Identified

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• MON-771 - Improvements in Patient-Reported Outcomes With Eneboparatide in Chronic Hypoparathyroidism Over 1 Year: A Phase 3, Randomized, Placebo-Controlled and Open-Label Study Assessing the Efficacy and Safety of Eneboparatide (CALYPSO)

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT

• ORF43-04 - Cross-Trait Genetic Architecture of Mineral Homeostasis

  Monday, June 15, 2026
  9:45 AM - 10:00 AM CT